Pasar al contenido principal

PREVENCION DEL CANCER DE MAMA MEDIANTE LA MODIFICACION DE LAS VIAS MOLECULARES IMPLICADAS EN LA INVOLUCION POSTLACTACIONAL

PID2023-153081OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  • García-Sancha, Natalia
  • Corchado Cobos, Roberto
Breast cancer is the most common malignancy among women globally, with incidence rates continuing to rise. A comprehensive understanding of its risk factors and the underlying biological mechanisms that drive tumor initiation is essential for developing effective prevention strategies. This review examines key non-modifiable risk factors, such as genetic predisposition, demographic characteristics, family history, mammographic density, and reproductive milestones, as well as modifiable risk factors like exogenous hormone exposure, obesity, diet, and physical inactivity. Importantly, reproductive history plays a dual role, providing long-term protection while temporarily increasing breast cancer risk shortly after pregnancy. Current chemoprevention strategies primarily depend on selective estrogen receptor modulators (SERMs), including tamoxifen and raloxifene, which have demonstrated efficacy in reducing the incidence of estrogen receptor-positive breast cancer but remain underutilized due to adverse effects. Emerging approaches such as aromatase inhibitors, RANKL inhibitors, progesterone antagonists, PI3K inhibitors, and immunoprevention strategies show promise for expanding preventive options. Understanding the interactions between risk factors, hormonal influences, and tumorigenesis is critical for optimizing breast cancer prevention and advancing safer, more targeted chemopreventive interventions, This work carried out in JPL’s laboratory, was supported by Grant SAF2017-88854R, funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grants PID2020-118527RB-I00 and PDC2021-121735-I00, funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”; Grant PID2023-153081OB-I00, funded by MCIN/AEI/10.13039/501100011039; the Regional Government of Castile and León (CSI144P20); and the “We can be heroes” charity. N.G.-S. was a recipient of an FPU fellowship (MECD-FPU17/00192). R.C.-C. was founded by a fellowship from the Spanish Regional Government of Castile and León., Peer reviewed